Synthesis and Characterization of 4-Thiobutyl-triphenylphosphonium-pantetheine, a Pantetheine Derivative

References (26)

1. 1 Delivery of bioactive molecules to mitochondria in vivo [DOI]
2. 2 A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease [DOI]
3. 3 The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients [DOI]
4. 4 Pantethine rescues a Drosophila model for pantothenate kinase–associated neurodegeneration [DOI]
5. 5 Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability [DOI]
6. 6 Protection against cerebral malaria by the low-molecular-weight thiol pantethine [DOI]
7. 7 Synthesis and Characterization of Thiobutyltriphenylphosphonium Bromide, a Novel Thiol Reagent Targeted to the Mitochondrial Matrix [DOI]
8. 8 Pantothenamides Are Potent, On-Target Inhibitors of Plasmodium falciparum Growth When Serum Pantetheinase Is Inactivated [DOI]
9. 9 Diverse biological activities of the vascular non-inflammatory molecules – The Vanin pantetheinases [DOI]
10. 10 Germline Deletion of Pantothenate Kinases 1 and 2 Reveals the Key Roles for CoA in Postnatal Metabolism [DOI]
11. 11 Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases [DOI]
12. 12 Structural Modification of Pantothenamides Counteracts Degradation by Pantetheinase and Improves Antiplasmodial Activity [DOI]
13. 13 Discovery of Small Molecule Vanin Inhibitors: New Tools To Study Metabolism and Disease [DOI]
14. 14 Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease [DOI]
15. 15 Pantethine, a derivative of vitamin B5 used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low– to moderate–cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation [DOI]
16. 16 Adverse Reactions to Oral Cysteamine Use in Nephropathie Cystinosis [DOI]
17. 17 Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice [DOI]
18. 18 Assay of the enzymatic hydrolysis of pantetheine [DOI]
19. 19 Metabolism of pantethine in cystinosis. [DOI]
20. 20 The Enzymatic Breakdown of Pantethine to Pantothenic Acid and Cystamine [DOI]
21. 21 Purification and properties of a pantetheine-hydrolyzing enzyme from pig kidney. [DOI]
22. 22 Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury [DOI]
23. 23 New Concept in Nutrition for the Maintenance of the Aging Eye Redox Regulation and Therapeutic Treatment of Cataract Disease; Synergism of Natural Antioxidant Imidazole-Containing Amino Acid-Based Compounds, Chaperone, and Glutathione Boosting Agents: A Systemic Perspective on Aging and Longevity Emerged From Studies in Humans [DOI]
24. 24 Toxicity studies of some derivatives of pantothenic acid [DOI]
25. 25 A “Ready-To-Use” fluorescent-labelled-cysteine-TBTP (4-thiobutyltriphenylphosphonium) synthon to investigate the delivery of non-permeable PNA (peptide nucleic acids)-based compounds to cells [DOI]
26. 26 Toxicity of Pantetheine. [DOI]

Cited by 0

No indexed citations yet.